The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The Alzheimer’s agitation developer is strengthening biostatistics, regulatory and AI-enabled data capabilities as its 146-patient study moves toward …
The August 11 operating report puts clinic growth, NeuroStar utilisation and cost discipline at the centre of the …
The August 11 agreement gives Sentynl a route to license the oral neutrophil elastase inhibitor while Mereo advances …
The company is cutting operating costs while preserving investment in casdozokitug and tagmokitug, with mature clinical updates expected …
The oncology company reported $1.7 billion in quarterly revenue and lifted full-year guidance as its flagship BTK inhibitor …
An August 5 public meeting convened by the Reagan-Udall Foundation for the FDA examined how approved medicines could …
Health Canada authorized the Phase 1 study of mRNA-1469 as an active outbreak in the Democratic Republic of …
Same-day announcements from Harbour BioMed and Ascletis show Chinese developers pairing discovery platforms with manufacturing scale, regulatory strategy, …
A Delaware jury awarded Yale and Biohaven $4 million after finding that Avilar Therapeutics and RA Capital willfully …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …